Results 21 to 30 of about 37,818 (285)
ClinicoEconomics and Outcomes Research, 2011 Tania Stafinski1, Devidas Menon2, Caroline Davis1, Christopher McCabe31Health Technology and Policy Unit, 2Health Policy and Management, School of Public Health, University of Alberta, Edmonton, Alberta, Canada; 3Academic Unit of Health Economics, Leeds ...
Stafinski T, Menon D, Davis C, McCabe C
doaj +2 more sources
Should annual cost of the drug inform reimbursement decisions? A perspective from China’s healthcare security system [PDF]
Frontiers in Public HealthBackgroundAn increasing number of countries worldwide, including China, have adopted Health Technology Assessment (HTA) and pharmacoeconomic (PE) principles, either comprehensively or partially, to inform drug reimbursement decisions.
Xiaochen Peng +5 more
doaj +2 more sources
Patterns in the influence of funding and reimbursement on the development and implementation of healthcare innovation: A systematic review [PDF]
Journal of Open Innovation: Technology, Market and ComplexityInnovation is considered essential to the quality and sustainability of healthcare systems. However, the path from innovative idea to adopted reality is complex and fraught with barriers.
Sanne Allers +3 more
doaj +2 more sources
Rationale for Establishing a Mechanism to Increase Reimbursement to Hypertension Specialists [PDF]
The Journal of Clinical Hypertension, 2013 Hypertension is an important public health problem both in the United States and worldwide, contributing to many forms of cardiovascular and renal diseases. Although great strides have been made in the proportion of the US population that achieves recommended blood pressure targets, many Americans still have undertreated and uncontrolled blood pressure
William J, Elliott +5 more
openaire +2 more sources
Effect of retirement on medical reimbursement expenses—evidence from China
Health Economics Review, 2023 Background Medical reimbursement in China is not for all diseases, and medical reimbursement expenses are not completely consistent with medical service demand, though the scope and proportion of medical reimbursement are gradually expanding.
Yuanyang Wu, Jiahui Pang, Hualei Yang
doaj +1 more source
Cancer Medicine, 2020 Objectives Value‐based pricing of oncology drugs provides a best estimate for the price of a drug, as it relates to the benefits it provides for individual patients. To date, the impact of value‐based pricing to reference cost‐effectiveness thresholds (λ)
Ambica Parmar +3 more
doaj +1 more source
The reimbursement coverage decisions and pricing rules for medical devices in Taiwan
, 2022 Medical technology is undergoing rapid transformations, and the classifications of medical devices have also expanded greatly; therefore, it is necessary to develop appropriate reimbursement policies and pricing mechanisms in a timely manner.
Huang, LY +5 more
core +1 more source
Analysis of changes in drug reimbursement based on the example of the limit groups containing beta-2 adrenergic drugs in Poland in the years 2012-2021 [PDF]
Farmacja Polska, 2022 Subject of the study The subject of the study is a price analysis of the limit groups of reimbursed beta-2 adrenergic drugs. Rationalisation of reimbursement expenditure, including generic substitution, is carried out in order to maximise health effects ...
Piotr Zbigniew Rykowski +3 more
doaj +1 more source
Frontiers in Pharmacology, 2017 Objectives: To explore whether Heberprot-P (an epidermal growth factor) is a cost-effective option for the treatment of advanced diabetic foot ulcer as an add-on therapy to good wound care (GWC) in Slovakia from the perspective of health care payers ...
Tomas Tesar +8 more
doaj +1 more source
Reimbursement decision-making system in Poland systematically compared to other countries
Frontiers in Pharmacology, 2023 Introduction: Our objective was to analyze and compare systematically and structurally reimbursement systems in Poland and other countries.Methods: The systems were selected based on recommendations issued by the Polish Agency for Health Technology ...
Aneta Mela +5 more
doaj +1 more source